{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T11:52:40Z","timestamp":1777981960936,"version":"3.51.4"},"reference-count":54,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To characterize trends and patterns in treatment characteristics and perioperative outcomes of patients with urothelial muscle\u2010invasive bladder cancer (MIBC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>We utilized the National Cancer Database to assess trends and patterns in treatment modalities (radical cystectomy [RC] with or without neoadjuvant\/adjuvant treatments, trimodal bladder\u2010sparing treatment [trimodal treatment], and others) among MIBC patients diagnosed between 2004 and 2017. We also assessed trends and patterns of short\u2010term post\u2010surgery outcomes, including 30\u2010day and 90\u2010day mortality, and readmissions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 83,259 MIBC patients, those who received RC, trimodal treatment, and transurethral resection of bladder tumor (TURBT) plus chemotherapy were 34,715 (41.7%), 7,372 (8.9%), and 6,171 (7.4%), respectively. A substantial proportion (29,314; 35.2%) of MIBC patients received other treatments, including TURBT\u2010only. From 2004 through 2017, the proportion of MIBC patients who utilized guideline\u2010recommended treatments, whether RC (from 36.4% to 42.8%) or trimodal treatment (from 7.9% to 10.2%), increased. Among those who received RC, there was a substantial increase in neoadjuvant chemotherapy (NAC) utilization, from 7.8% to 29.4%. Conversely, utilization of RC without perioperative treatments decreased from 62.3% to 32.7%. There was a significant decrease in 30\u2010day (2.8%\u20131.8%) and 90\u2010day (7.1%\u20135.3%) mortality rates among RC recipients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>There was a shift in treatment modalities for MIBC, with increased utilization of RC with NAC. A decrease in post\u2010surgery mortality rates may indicate improved outcomes, although the unmet need for NAC utilization requires further investigation.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.70644","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T11:47:15Z","timestamp":1739447235000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Treatment Patterns and Radical Cystectomy Outcomes in Patients Diagnosed With Urothelial Nonmetastatic Muscle\u2010Invasive Bladder Cancer in the United States"],"prefix":"10.1002","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8653-9338","authenticated-orcid":false,"given":"Bernard Bright","family":"Davies\u2010Teye","sequence":"first","affiliation":[{"name":"Department of Practice, Sciences, and Health Outcomes Research University of Maryland School of Pharmacy  Baltimore Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Minhaj","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"University of Maryland School of Medicine  Baltimore Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Rahway New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abree","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Practice, Sciences, and Health Outcomes Research University of Maryland School of Pharmacy  Baltimore Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet","family":"Burcu","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Rahway New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8547-1810","authenticated-orcid":false,"given":"Eberechukwu","family":"Onukwugha","sequence":"additional","affiliation":[{"name":"Department of Practice, Sciences, and Health Outcomes Research University of Maryland School of Pharmacy  Baltimore Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nader","family":"Hanna","sequence":"additional","affiliation":[{"name":"University of Maryland School of Medicine  Baltimore Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.EURURO.2011.03.023"},{"key":"e_1_2_12_3_1","unstructured":"P. E.Clark P. E.Spiess N.Agarwal et\u00a0al. \u201cNCCN Guidelines Insights Bladder Cancer Version 2.2016 Featured Updates to the NCCN Guidelines.\u201d"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.0011"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.9797"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003981"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000001855"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.12585"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA022148"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464\u2010410X.1988.tb09152.x"},{"key":"e_1_2_12_11_1","unstructured":"T.Flaig P.Spiess M.Abern et\u00a0al. \u201cNCCN Guidelines Version 1.2024 Bladder Cancer 2024.\u201d"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/https"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.5405"},{"key":"e_1_2_12_14_1","unstructured":"CoC \u201cNational Cancer Database Participant User File 2017 Data Dictionary \u201d 2020."},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.46883\/2022.25920939"},{"key":"e_1_2_12_16_1","unstructured":"ACS \u201cAbout the National Cancer Database \u201d 2023 https:\/\/www.facs.org\/quality\u2010programs\/cancer\u2010programs\/national\u2010cancer\u2010database\/about\/."},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2023.0652"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.07.056"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/1073274818789355"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.6905"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010022\u201025425\u20106"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2023.101435"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2023.100560"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11091239"},{"key":"e_1_2_12_25_1","unstructured":"NCDB\u201cThe Commission on Cancer\u2019s National Cancer Database Participant User File (PUF) Data Use Agreement \u201d (2020)."},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885\u2010023\u201010798\u20102"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12957\u2010023\u201003161\u2010z"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.22465\/juo.244801000050"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/UPJ.0000000000000146"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2018.06.001"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1106106"},{"key":"e_1_2_12_32_1","first-page":"467","volume-title":"Bladder Cancer","author":"Mak R.","year":"2018"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.12601"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.3233\/BLC\u2010170134"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14235740"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345\u2010021\u201003776\u20105"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.4111\/ICU.2020.61.4.390"},{"key":"e_1_2_12_38_1","unstructured":"AUA \u201cTreatment of Non\u2010Metastatic Muscle\u2010Invasive Bladder Cancer: AUA\/ASCO\/ASTRO\/SUO Guideline. American Urological Association Website.\u201d"},{"issue":"4","key":"e_1_2_12_39_1","first-page":"1","article-title":"First\u2010Of\u2010Its\u2010Kind Multidisciplinary Guidelines for MIBC Treatment","volume":"7","author":"Katz A.","year":"2017","journal-title":"OncologyLive"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2020.02.001"},{"issue":"2","key":"e_1_2_12_41_1","first-page":"1","article-title":"Future Directions of Neoadjuvant Therapy in Muscle\u2010Invasive Bladder Cancer","volume":"7","author":"Koshkin V.","year":"2018","journal-title":"Journal of Targeted Therapies in Cancer"},{"key":"e_1_2_12_42_1","unstructured":"NCCN \u201cNCCN Guidelines for Patients: Bladder Cancer \u201d 2023."},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1159\/000503398"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS15010168"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.7393"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.JURO.2010.06.007"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1159\/000524578"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.CURRPROBLCANCER.2014.06.001"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13154349"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.15984"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00428\u2010021\u201003264\u20106"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2020.100264"},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6768"},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241612596"},{"key":"e_1_2_12_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2017.16"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.70644","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T22:45:08Z","timestamp":1744929908000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.70644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1002\/cam4.70644"],"URL":"https:\/\/doi.org\/10.1002\/cam4.70644","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"2024-09-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70644"}}